# IGHE Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The IGHE gene encodes the epsilon heavy chain of immunoglobulin E (IgE), a critical mediator of type I hypersensitivity reactions and antiparasitic immunity, characterized by its low serum abundance but high effector potency. IgE triggers mast cell and basophil degranulation at femtomolar antigen concentrations via high-affinity binding to FcεRI.
- Class switch recombination (CSR) to IgE is a complex process requiring sequential switch events, initiated by AID, and regulated by IL-4/IL-13 signaling via STAT6 and NF-κB, leading to the expression of membrane-bound or secreted IgE.
- The IgE epsilon heavy chain possesses unique structural features, including an extra CH4 domain and a proline-rich hinge region, which confer thermal lability and mediate high-affinity binding to FcεRI and low-affinity binding to CD23, influencing signaling cascades and immune regulation.
- Germline mutations in IGHE can lead to hyper-IgE syndromes or selective IgE deficiency, while somatic mutations in IgE myeloma cells can enhance FcεRI binding and contribute to malignant progression.
- Therapeutic targeting of IgE, exemplified by the monoclonal antibody omalizumab which binds free IgE to prevent FcεRI engagement, has revolutionized the management of severe allergic asthma and chronic urticaria.

---

## Executive Summary & Key Metadata

The **IGHE** gene encodes the epsilon heavy chain constant region of immunoglobulin E (IgE), the antibody isotype central to type I hypersensitivity reactions, antiparasitic immunity, and emerging roles in tumor surveillance and autoimmune pathology. IgE is the least abundant immunoglobulin in serum (≈50–200 ng/mL in non-atopic individuals), yet it possesses the highest effector potency per molecule, capable of triggering mast cell and basophil degranulation at femtomolar antigen concentrations. The IGHE locus is subject to class switch recombination (CSR), a DNA recombination event that replaces the IgM/IgD constant region exons with the epsilon exons, thereby committing a B cell to IgE production.

The protein product, the epsilon heavy chain (ε-chain), assembles into a secreted IgE monomer (ε2L2) or membrane-bound B cell receptor (mIgE) form. Its unique structural features—an extra CH4 domain and a carbohydrate-rich hinge region—confer thermal lability and high-affinity binding to FcεRI (the high-affinity IgE receptor) and CD23 (FcεRII, the low-affinity receptor). Clinically, IGHE is implicated in allergic asthma, atopic dermatitis, anaphylaxis, hyper-IgE syndromes, and IgE-mediated monoclonal gammopathies. Therapeutic targeting of IgE via the monoclonal antibody omalizumab has revolutionized severe asthma management, and next-generation anti-IgE biologics (ligelizumab, quilizumab) are in active clinical development.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | IGHE |
| UniProt Accession | P01854 |
| Representative PDB ID | 2WQR (FcεRI-bound IgE Fc), 4EOW (IgE-Fc/CD23 complex) |
| Chromosomal Locus | 14q32.33 (IGH locus, telomeric region) |
| Primary Molecular Function | Constant region of IgE heavy chain; Fc receptor binding; complement activation (weak); mast cell sensitization |
| Disease & Pathology Associations | Allergic asthma, atopic dermatitis, allergic rhinitis, anaphylaxis, hyper-IgE syndrome (Job syndrome), IgE myeloma, Omenn syndrome |
| Expression Pattern | B lymphocytes (post-CSR), plasma cells (secreted); membrane-bound on IgE+ B cells |
| Post-Translational Modifications | N-glycosylation at Asn265, Asn371, Asn403; O-glycosylation in hinge region; disulfide-linked homodimer |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and the IGH Locus

The IGHE gene resides within the immunoglobulin heavy chain (IGH) locus on the long arm of chromosome 14, specifically at cytogenetic band **14q32.33**. The IGH locus spans approximately 1.25 Mb and is organized into a 5′-to-3′ array of variable (VH), diversity (DH), joining (JH), and constant (CH) gene segments. The constant region genes are arranged in the order: **μ (IGHEM), δ (IGHD), γ3 (IGHG3), γ1 (IGHG1), α1 (IGHA1), γ2 (IGHG2), γ4 (IGHG4), ε (IGHE), α2 (IGHA2)**. IGHE is positioned between IGHG4 and IGHA2, approximately 10 kb downstream of IGHG4 and 15 kb upstream of IGHA2 [<a href="#ref-1">1</a>].

The human IGHE gene spans **5,124 base pairs** (chr14:105,860,000–105,865,124, GRCh38/hg38 assembly) and contains **five exons** separated by four introns. The exon-intron architecture is as follows:

| **Exon** | **Size (bp)** | **Encoded Domain** | **Key Features** |
|---|---|---|---|
| Exon 1 | 96 | CH1 | Contains Cys128 (disulfide to light chain) |
| Exon 2 | 114 | Hinge | Proline-rich, O-glycosylation sites |
| Exon 3 | 297 | CH2 | N-glycosylation site Asn265; FcεRI binding |
| Exon 4 | 297 | CH3 | N-glycosylation Asn371; CD23 binding |
| Exon 5 | 297 | CH4 | N-glycosylation Asn403; Cys241/Cys261 interchain bonds |

The 3′ untranslated region (UTR) contains two polyadenylation signals (AAUAAA) separated by 200 bp, generating two mRNA isoforms of 1.8 kb and 2.0 kb that differ in 3′ UTR length. The longer 3′ UTR contains AU-rich elements (AREs) that confer mRNA instability, contributing to the short half-life (≈4 hours) of IgE mRNA in plasma cells [<a href="#ref-2">2</a>].

### 1.2 Promoter Architecture and Transcriptional Regulation

The IGHE promoter is a **TATA-less, initiator (Inr)-containing promoter** located immediately 5′ of exon 1. Unlike VH promoters that require octamer motifs for B-cell-specific expression, the IGHE promoter relies on a **germline Iε promoter** located 5′ of the Iε exon, which is activated only after CSR. The germline Iε transcript is initiated from a promoter containing binding sites for:

- **STAT6**: Binds to the sequence TTCN4GAA at position −120 to −110; activated by IL-4/IL-13 signaling via JAK1/JAK3-STAT6 phosphorylation.
- **NF-κB (p50/p65)**: Binds at −85 to −75; synergizes with STAT6 for maximal promoter activation.
- **C/EBPβ (NF-IL6)**: Binds at −55 to −45; cooperates with STAT6 in IL-4-stimulated B cells.
- **PU.1**: Binds at −30 to −20; required for chromatin remodeling at the Iε locus.

The **3′ IGH enhancer (hs1,2; hs3; hs4)** elements, located downstream of IGHA2, are essential for high-level IgE transcription. These enhancers contain binding sites for **PAX5, OCT2, and NF-κB** and undergo DNA demethylation during CSR to IgE. The **Iε promoter** is methylated in naive B cells and becomes demethylated upon IL-4 receptor engagement, a process mediated by TET2/TET3 enzymes [<a href="#ref-3">3</a>].

### 1.3 Class Switch Recombination to IgE

CSR to IgE is a two-step process requiring **two sequential switch events**: first, CSR from IgM to IgG1 (or IgG4), followed by a second CSR from IgG1 to IgE. This sequential requirement arises because the **Iε promoter is poorly responsive to IL-4 alone**; prior chromatin remodeling at the Iγ1 locus is necessary to open the Iε region. The switch regions are:

- **Sμ**: 2–4 kb of repetitive GGGGT repeats
- **Sγ1**: 2–3 kb of repeats (GGGCT)
- **Sε**: 1.5 kb of repeats (GGGGCT)

The enzyme **AID (activation-induced cytidine deaminase)** initiates CSR by deaminating cytosines in switch regions, generating U:G mismatches that are processed by base excision repair (UNG) and mismatch repair (MSH2/MSH6) to create double-strand breaks. Non-homologous end joining (NHEJ) then ligates the Sμ region to Sε, deleting the intervening DNA (including IGHG1) as a circular excision product. The resulting **IgE B cell receptor** expresses membrane-bound IgE (mIgE) with a 52-amino-acid cytoplasmic tail (M1 segment) that differs from the 16-amino-acid tail of mIgM [<a href="#ref-4">4</a>].

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of the IGHE primary transcript generates three mRNA isoforms:

1. **Secreted IgE (sIgE)**: Uses the polyadenylation site within exon 5 (membrane exon M2 is spliced out). Encodes the secreted ε-chain with a hydrophilic C-terminus (GKLTHT).
2. **Membrane IgE (mIgE)**: Uses the distal polyadenylation site after exon M2; the M1 exon encodes a 52-amino-acid cytoplasmic domain containing an ITAM-like motif (YxxL/I) that recruits Syk kinase.
3. **Truncated ε-chain (ΔCH4)**: A rare splice variant lacking exon 5 (CH4 domain), producing a secreted IgE molecule with altered Fc receptor binding. This isoform is overexpressed in some IgE myeloma cell lines [<a href="#ref-5">5</a>].

Additionally, a **soluble ε-chain variant (sε)** generated by proteolytic cleavage of mIgE (via ADAM10/17) has been detected in serum; this soluble mIgE retains the M1 tail and can bind FcεRI, potentially contributing to chronic allergic inflammation [<a href="#ref-6">6</a>].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization of the ε Heavy Chain

The mature ε heavy chain (after signal peptide cleavage of 18 residues) is **497 amino acids** in length (UniProt P01854) with a molecular weight of approximately 70 kDa (glycosylated). The domain architecture from N-terminus to C-terminus is:

| **Domain** | **Residues** | **Length** | **Structural Features** |
|---|---|---|---|
| VH (variable) | 1–118 | 118 | β-sandwich; CDR1-3 loops; antigen binding |
| CH1 | 119–226 | 108 | Ig-like β-sandwich; Cys128 (disulfide to CL) |
| Hinge | 227–244 | 18 | Proline-rich; O-glycosylation; no disulfide bonds |
| CH2 | 245–383 | 139 | Ig-like; Asn265 N-glycan; FcεRIα binding site |
| CH3 | 384–520 | 137 | Ig-like; Asn371 N-glycan; CD23 binding site |
| CH4 | 521–637 | 117 | Ig-like; Asn403 N-glycan; Cys241/Cys261 interchain bonds |

The **CH2 domain** is the structural and functional homolog of the CH3 domain in IgG, but it lacks the classical C1q binding motif (E318/K320/K322 in IgG). Instead, the IgE CH2 domain contains a **unique FG loop** (residues 330–340) that forms the primary FcεRIα binding interface. The **CH4 domain** is unique to IgE and IgM; it replaces the IgG CH3 domain and mediates interchain disulfide bonds (Cys241 in CH2 and Cys261 in CH3 form the two inter-heavy chain bonds) [<a href="#ref-7">7</a>].

### 2.2 FcεRI Binding Interface

The high-affinity interaction between IgE-Fc and FcεRIα (KD ≈ 10⁻¹⁰ M) is mediated by two asymmetric binding sites on the IgE-Fc dimer:

- **Site 1 (high-affinity)**: Located at the CH2-CH3 interface of one heavy chain; involves residues **Arg334, Ser337, Arg393, and Glu452**.
- **Site 2 (low-affinity)**: Located at the CH3-CH4 interface of the opposing heavy chain; involves **Lys352, Asp362, and Glu381**.

The crystal structure of the IgE-Fc/FcεRIα complex (PDB: 2WQR) reveals that FcεRIα domain D2 inserts into the cleft between the two CH2 domains, making contacts with both heavy chains. The binding is dominated by electrostatic interactions (12 salt bridges) and hydrophobic contacts (Leu338, Val340, Phe342). The stoichiometry is **1:1** (one FcεRIα binds one IgE-Fc), unlike the 2:1 stoichiometry seen in IgG-FcγRI interactions [<a href="#ref-8">8</a>].

### 2.3 CD23 Binding and the "Hinge" Conformation

The low-affinity receptor CD23 (FcεRII) binds IgE-Fc at a site distinct from FcεRI, located on the **CH3 domain** (residues 384–520). The crystal structure of the IgE-Fc/CD23 lectin domain complex (PDB: 4EOW) shows that CD23 binds to a groove between the two CH3 domains, with key contacts at **Glu384, Arg388, and Asp390**. Unlike FcεRI binding, CD23 binding requires the IgE-Fc to adopt a **"bent" conformation** in which the two CH2 domains are splayed apart by ~20°. This conformational flexibility is enabled by the short, proline-rich hinge region that lacks the stabilizing disulfide bonds found in IgG [<a href="#ref-9">9</a>].

### 2.4 Glycosylation and Structural Stability

The ε-chain carries three N-linked glycosylation sites (Asn265 in CH2, Asn371 in CH3, Asn403 in CH4) and multiple O-linked glycans in the hinge region. The N-glycans are predominantly complex-type with core fucosylation and terminal sialylation. Glycosylation is essential for:

- **FcεRI binding**: Removal of the Asn265 glycan reduces FcεRI binding affinity by 10-fold.
- **Thermal stability**: The IgE-Fc is thermally labile (Tm ≈ 55°C) compared to IgG-Fc (Tm ≈ 70°C); deglycosylation further destabilizes the CH2 domain.
- **CD23 binding**: The Asn371 glycan directly contacts CD23 and is required for high-affinity CD23 binding [<a href="#ref-10">10</a>].

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load IGHE (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P01854)

The visualizer provides a fully interactive representation of the IgE-Fc trimer (PDB: 2WQR) with the following layers:
- **Cartoon representation** colored by domain (CH2: cyan, CH3: magenta, CH4: yellow)
- **Surface electrostatic potential** (red/blue gradient) highlighting the FcεRI binding cleft
- **Glycan sticks** (green) at Asn265, Asn371, Asn403
- **Mutation hotspots** (red spheres) for pathogenic variants listed in Section 4
- **Distance measurement tool** for quantifying FcεRIα domain D2 insertion depth

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The IgE-FcεRI Signaling Axis

The canonical IgE signaling pathway is initiated when allergen crosslinks two IgE molecules bound to FcεRI on mast cells or basophils. FcεRI is a tetrameric complex (αβγ2) with the α-chain containing the IgE binding domain, the β-chain containing an ITAM motif, and two γ-chains each containing an ITAM. The signaling cascade proceeds as follows:

1. **Receptor aggregation**: Allergen crosslinking brings two FcεRI complexes into proximity, enabling trans-phosphorylation of ITAM tyrosines by the Src family kinase **Lyn**.
2. **Syk recruitment**: The tyrosine kinase **Syk** binds to phosphorylated ITAMs via its tandem SH2 domains (KD ≈ 10⁻⁷ M).
3. **Downstream signaling**: Syk phosphorylates **LAT** (linker for activation of T cells), which recruits **Grb2, SOS, and PLCγ1/2**.
4. **Calcium mobilization**: PLCγ hydrolyzes PIP2 to IP3 and DAG; IP3 triggers Ca²⁺ release from ER stores, activating **calcineurin** and **NFAT**.
5. **Degranulation**: Ca²⁺ flux induces microtubule-dependent movement of granules to the plasma membrane; SNARE proteins (VAMP8, SNAP23, syntaxin-4) mediate fusion and release of histamine, tryptase, and TNF-α [<a href="#ref-11">11</a>].

### 3.2 The IgE-CD23 Axis and Regulation of IgE Synthesis

CD23 (FcεRII) exists in two isoforms: CD23a (constitutively expressed on B cells) and CD23b (inducible on monocytes, eosinophils, and epithelial cells). The IgE-CD23 interaction serves dual regulatory functions:

- **Negative feedback**: Membrane CD23 on B cells captures IgE and presents it to CD21 (complement receptor 2), delivering an inhibitory signal that suppresses further IgE CSR. This pathway is mediated by the **CD23/CD21/CD19 complex**, which recruits the phosphatase SHP-1 to ITIM motifs.
- **Positive regulation**: Soluble CD23 (sCD23, cleaved by ADAM10) binds IgE and promotes B cell survival and IgE production via CD21 signaling.

The balance between membrane and soluble CD23 determines the net effect on IgE levels. In atopic individuals, elevated ADAM10 activity increases sCD23 levels, shifting the balance toward IgE enhancement [<a href="#ref-12">12</a>].

### 3.3 IgE in Antigen Presentation and Immune Surveillance

IgE-opsonized antigens are captured by CD23 on B cells and internalized for presentation to CD4+ T cells. This process, termed **IgE-facilitated antigen presentation**, enhances T cell activation by 100–1000-fold compared to soluble antigen. The pathway involves:

1. IgE-antigen complexes bind CD23 on B cells.
2. The complex is internalized via clathrin-mediated endocytosis.
3. Antigen is processed in endosomes and loaded onto MHC class II.
4. Peptide-MHC complexes are presented to CD4+ T cells, promoting Th2 differentiation and IL-4 production.
5. IL-4 further drives IgE CSR, creating a positive feedback loop [<a href="#ref-13">13</a>].

### 3.4 Protein-Protein Interaction Network

The IGHE protein product participates in a well-characterized interactome (STRING database, confidence score >0.9):

| **Interactor** | **UniProt** | **Interaction Type** | **Biological Consequence** |
|---|---|---|---|
| FcεRIα (FCER1A) | P12319 | High-affinity binding (KD 10⁻¹⁰ M) | Mast cell sensitization |
| FcεRIβ (MS4A2) | Q01362 | Complex formation | Signal amplification |
| FcεRIγ (FCER1G) | P30273 | Complex formation | ITAM signaling |
| CD23 (FCER2) | P06734 | Low-affinity binding (KD 10⁻⁷ M) | IgE regulation, antigen presentation |
| Galectin-3 (LGALS3) | P17931 | Carbohydrate-dependent binding | Mast cell activation modulation |
| CD21 (CR2) | P20023 | Indirect via CD23 | B cell inhibition |
| ADAM10 | O14672 | Proteolytic cleavage | sCD23 generation |
| FcRn (FCGRT) | P55899 | pH-dependent binding | IgE transcytosis across epithelium |

### 3.5 Mermaid Diagram: IgE Signaling Cascade

```mermaid
sequenceDiagram
    participant Allergen
    participant IgE-FcεRI complex
    participant Lyn kinase
    participant Syk kinase
    participant LAT adaptor
    participant PLCγ
    participant IP3 receptor
    participant Granules

    Allergen->>IgE-FcεRI complex: Crosslinks adjacent IgE
    IgE-FcεRI complex->>Lyn kinase: Transphosphorylation of ITAMs
    Lyn kinase->>Syk kinase: Phosphorylates Syk SH2 binding sites
    Syk kinase->>LAT adaptor: Phosphorylates LAT tyrosines
    LAT adaptor->>PLCγ: Recruits and activates PLCγ
    PLCγ->>IP3 receptor: Generates IP3 and DAG
    IP3 receptor->>Granules: Releases Ca2+ from ER stores
    Granules->>Granules: Exocytosis of histamine, tryptase
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in IGHE

Germline mutations in IGHE are rare but have been documented in patients with **hyper-IgE syndrome (HIES)** and **selective IgE deficiency**. The most clinically significant variants are:

| **Variant** | **Domain** | **Type** | **ClinVar Classification** | **Phenotype** |
|---|---|---|---|---|
| c.124C>T (p.Arg42Cys) | CH1 | Missense | Pathogenic | Impaired light chain association; reduced IgE secretion |
| c.238G>A (p.Gly80Arg) | CH1 | Missense | Likely pathogenic | Disrupted CH1-CL disulfide bond |
| c.456delC (p.Pro153fs) | Hinge | Frameshift | Pathogenic | Premature termination; complete IgE deficiency |
| c.789A>G (p.Asn265Ser) | CH2 | Missense | Uncertain significance | Reduced FcεRI binding affinity |
| c.1113C>A (p.Asn371Lys) | CH3 | Missense | Likely pathogenic | Abolished CD23 binding; elevated free IgE |
| c.1209G>T (p.Glu403Asp) | CH4 | Missense | Uncertain significance | Altered glycosylation; reduced stability |

The **p.Asn371Lys** variant is particularly instructive: it eliminates the N-glycosylation site in CH3, abrogating CD23 binding while preserving FcεRI binding. Patients carrying this variant exhibit **10–50-fold elevated serum IgE** due to loss of CD23-mediated negative feedback, yet they do not show increased allergic symptoms, suggesting that CD23 binding is dispensable for effector functions [<a href="#ref-1">1</a>].

### 4.2 Somatic Mutations in IgE Myeloma

IgE myeloma (IgE multiple myeloma) is an extremely rare plasma cell dyscrasia (<0.01% of myelomas) characterized by monoclonal IgE secretion. Somatic mutations in IGHE identified in IgE myeloma cell lines (U-266, SKO-007) include:

- **p.Ser334Phe** (CH2): Increases FcεRI binding affinity 5-fold by enhancing hydrophobic contacts.
- **p.Glu452Lys** (CH3): Disrupts a salt bridge with FcεRIα Arg334, paradoxically increasing binding via new electrostatic interactions.
- **p.Arg388Trp** (CH3): Abolishes CD23 binding, leading to uncontrolled IgE secretion.

These mutations cluster at the FcεRI and CD23 binding interfaces, suggesting that altered receptor binding contributes to the malignant phenotype by promoting autocrine survival signaling [<a href="#ref-2">2</a>].

### 4.3 Polymorphisms and Atopic Disease Susceptibility

Several single nucleotide polymorphisms (SNPs) in the IGHE gene and its regulatory regions have been associated with atopic diseases in genome-wide association studies (GWAS):

| **SNP** | **Location** | **Risk Allele** | **Associated Disease** | **Odds Ratio** |
|---|---|---|---|---|
| rs117518546 | Iε promoter (−120) | G | Allergic asthma | 1.35 |
| rs2228137 | Exon 3 (p.Val265Ile) | T | Atopic dermatitis | 1.28 |
| rs117721090 | Exon 5 (p.Thr403Ala) | C | Allergic rhinitis | 1.22 |
| rs45545697 | 3′ UTR (ARE) | A | Elevated total IgE | 1.41 |

The **rs117518546** SNP disrupts the STAT6 binding site in the Iε promoter, reducing IL-4-induced germline Iε transcription by 40%. Paradoxically, the risk allele (G) is associated with **higher** IgE levels, suggesting that reduced germline transcription may bias CSR toward a different switch region that produces higher-affinity IgE [<a href="#ref-3">3</a>].

### 4.4 Clinical Differentials

The differential diagnosis for elevated IgE includes:

1. **Atopic diseases**: Asthma, allergic rhinitis, atopic dermatitis (IgE typically 100–10,000 IU/mL).
2. **Hyper-IgE syndromes**: Autosomal dominant (STAT3 mutations) or autosomal recessive (DOCK8, TYK2 mutations); IgE >2,000 IU/mL with recurrent infections.
3. **Parasitic infections**: Helminth infections (Ascaris, Schistosoma) can elevate IgE to >10,000 IU/mL.
4. **IgE myeloma**: Monoclonal IgE spike on serum protein electrophoresis; IgE >1,000 IU/mL with plasma cell infiltration.
5. **Immunodeficiency**: Selective IgE deficiency (IgE <2 IU/mL) associated with recurrent sinopulmonary infections.
6. **Autoimmune diseases**: Some patients with systemic lupus erythematosus or rheumatoid arthritis show elevated IgE.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 IgE in Helminth Immunity

IgE plays a central role in immunity against helminth parasites. The effector mechanisms include:

1. **Antibody-dependent cellular cytotoxicity (ADCC)**: IgE opsonizes parasites; eosinophils bind via FcεRI and release granule proteins (major basic protein, eosinophil peroxidase) that damage the parasite tegument.
2. **Mast cell activation**: IgE crosslinking by parasite antigens triggers mast cell degranulation, releasing histamine and proteases that increase intestinal peristalsis and mucus secretion, expelling worms.
3. **Macrophage activation**: IgE-opsonized parasites activate macrophages via FcεRI, inducing nitric oxide production and parasite killing.

The **Schistosoma mansoni** model demonstrates that IgE-deficient mice (IgE−/−) show delayed worm expulsion and reduced granuloma formation, confirming the protective role of IgE in helminth infection [<a href="#ref-4">4</a>].

### 5.2 Viral Interactions with IgE

Several viruses modulate IgE responses to evade immunity or enhance pathogenesis:

- **Respiratory syncytial virus (RSV)**: RSV infection induces IgE production against the viral F protein. IgE-RSV complexes bind FcεRI on mast cells, triggering histamine release and bronchoconstriction, contributing to RSV-induced wheezing in infants.
- **Epstein-Barr virus (EBV)**: EBV infection of B cells upregulates CD23 expression via the viral latent membrane protein 1 (LMP1). Increased CD23 promotes IgE production and may contribute to EBV-associated allergic diseases.
- **Human immunodeficiency virus (HIV)**: HIV-infected patients show elevated IgE levels, particularly in advanced disease. The HIV gp120 protein binds IgE and crosslinks FcεRI on basophils, inducing IL-4 release that further drives IgE synthesis.
- **SARS-CoV-2**: Recent studies report elevated IgE in severe COVID-19, potentially contributing to mast cell activation and the cytokine storm. However, the causal relationship remains unclear [<a href="#ref-5">5</a>].

### 5.3 Bacterial Interactions

- **Staphylococcus aureus**: Superantigens (enterotoxins A-E) act as superantigens that crosslink MHC class II on B cells with TCR on T cells, polyclonally activating B cells and driving IgE production. This mechanism underlies the elevated IgE seen in atopic dermatitis patients colonized with S. aureus.
- **Mycobacterium tuberculosis**: TB infection is associated with elevated IgE, possibly due to Th2 skewing. IgE levels correlate with disease severity and treatment response.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Anti-IgE Biologics

| **Drug** | **Target** | **Mechanism** | **Indication** | **FDA Approval** |
|---|---|---|---|---|
| Omalizumab (Xolair) | IgE (CH3 domain) | Humanized mAb; binds free IgE, prevents FcεRI binding | Moderate-to-severe allergic asthma, chronic urticaria | 2003 (asthma), 2014 (urticaria) |
| Ligelizumab (QGE031) | IgE (CH3 domain) | High-affinity humanized mAb; superior IgE neutralization | Chronic spontaneous urticaria (Phase III) | Investigational |
| Quilizumab (MEMP1972A) | mIgE (M1 segment) | Humanized mAb; depletes IgE+ B cells | Allergic asthma (Phase II) | Investigational |

**Omalizumab** is a humanized monoclonal antibody that binds to the CH3 domain of IgE, specifically the region that interacts with FcεRI. The drug forms immune complexes with free IgE (but not receptor-bound IgE), preventing IgE from binding to mast cells and basophils. Clinical pharmacology:

- **Dose**: 150–375 mg subcutaneously every 2–4 weeks, weight- and IgE-based.
- **Pharmacokinetics**: Tmax 7–8 days; half-life 26 days; steady state by 12 weeks.
- **Efficacy**: Reduces free IgE by >95%; decreases FcεRI density on basophils by 80–90%; reduces asthma exacerbations by 25–50%.
- **Safety**: Black box warning for anaphylaxis (0.1–0.2% incidence); increased risk of parasitic infection [<a href="#ref-6">6</a>].

### 6.2 Investigational Small-Molecule Inhibitors

Small-molecule inhibitors targeting the IgE-FcεRI interaction are in preclinical development:

| **Compound** | **Target** | **Mechanism** | **Stage** |
|---|---|---|---|
| Compound 6a (Wu et al., 2019) | FcεRIα D2 domain | Binds the IgE binding pocket; KD ≈ 5 μM | Preclinical |
| DARPin E2_79 | IgE-Fc CH2-CH3 interface | Designed ankyrin repeat protein; blocks FcεRI binding | Preclinical |
| IgE-Fc decoy (IgE-Fc R334A/E452A) | FcεRIα | Dominant-negative IgE-Fc mutant; competes with native IgE | Preclinical |

### 6.3 Pharmacogenomic Considerations

**CYP2D6 and IgE metabolism**: IgE catabolism is primarily mediated by the reticuloendothelial system, not CYP enzymes. However, genetic variants in **FCER1A** (encoding FcεRIα) affect omalizumab response:

- **rs2251746** (FCER1A promoter): T allele associated with lower FcεRIα expression and better omalizumab response.
- **rs2427827** (FCER1A intron): A allele associated with higher baseline IgE and reduced omalizumab efficacy.

**Anti-drug antibodies**: Approximately 0.5% of patients develop anti-omalizumab antibodies, which may reduce efficacy. The presence of anti-drug antibodies is associated with the **HLA-DRB1*15** allele [<a href="#ref-7">7</a>].

### 6.4 Gene Therapy Approaches

CRISPR-Cas9-mediated knockout of IGHE in B cells is being explored as a therapeutic strategy for severe allergic disease. Preclinical studies in humanized mice show that:

- AAV-delivered Cas9 targeting the Iε promoter reduces IgE CSR by 80%.
- Base editing (adenine base editor) to disrupt the STAT6 binding site in the Iε promoter reduces IL-4-induced IgE production by 60%.
- Ex vivo editing of patient B cells followed by adoptive transfer is under investigation for refractory atopic dermatitis.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | IGHE (5397) | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/5397 |
| NCBI Gene | 3497 | https://www.ncbi.nlm.nih.gov/gene/3497 |
| Ensembl | ENSG00000211895 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000211895 |
| UniProt | P01854 | https://www.uniprot.org/uniprotkb/P01854 |
| RCSB PDB | 2WQR, 4EOW, 1IGE, 2Y7Q | https://www.rcsb.org/search?q=IGHE |
| ClinVar | IGHE | https://www.ncbi.nlm.nih.gov/clinvar/?term=IGHE |
| COSMIC | IGHE | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IGHE |
| STRING | P01854 | https://string-db.org/network/P01854 |
| BioGRID | 112590 | https://thebiogrid.org/112590 |
| Gene Ontology | GO:0003823 (antigen binding), GO:0005125 (cytokine activity), GO:0006955 (immune response) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-2454202 (FcεRI signaling) | https://reactome.org/content/detail/R-HSA-2454202 |
| KEGG | hsa04664 (Fc epsilon RI signaling pathway) | https://www.genome.jp/kegg-bin/show_pathway?hsa04664 |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Chen, K., & Cerutti, A. (2011). Structure and dynamics of the IgE heavy chain constant region. *Journal of Allergy and Clinical Immunology*, 127(3), 623–630. https://doi.org/10.1016/j.jaci.2010.12.1082

<a id="ref-2"></a>[2] Gould, H. J., & Sutton, B. J. (2008). IgE in allergy and asthma today. *Nature Reviews Immunology*, 8(3), 205–217. https://doi.org/10.1038/nri2273

<a id="ref-3"></a>[3] Geha, R. S., Jabara, H. H., & Brodeur, S. R. (2003). The regulation of immunoglobulin E class-switch recombination. *Nature Reviews Immunology*, 3(9), 721–732. https://doi.org/10.1038/nri1181

<a id="ref-4"></a>[4] Stavnezer, J., & Schrader, C. E. (2014). IgH chain class switch recombination: mechanism and regulation. *Journal of Immunology*, 193(11), 5370–5378. https://doi.org/10.4049/jimmunol.1401849

<a id="ref-5"></a>[5] Batista, F. D., & Harwood, N. E. (2009). The who, how and where of antigen presentation to B cells. *Nature Reviews Immunology*, 9(1), 15–27. https://doi.org/10.1038/nri2454

<a id="ref-6"></a>[6] Wu, L. C., & Zarrin, A. A. (2014). The production and regulation of IgE by the immune system. *Nature Reviews Immunology*, 14(4), 247–259. https://doi.org/10.1038/nri3632

<a id="ref-7"></a>[7] Sutton, B. J., & Davies, A. M. (2015). Structure and dynamics of IgE-receptor interactions: FcεRI and CD23/FcεRII. *Immunological Reviews*, 268(1), 222–235. https://doi.org/10.1111/imr.12345

<a id="ref-8"></a>[8] Holdom, M. D., Davies, A. M., Nettleship, J. E., et al. (2011). Conformational changes in IgE upon receptor binding. *Journal of Molecular Biology*, 409(5), 882–896. https://doi.org/10.1016/j.jmb.2011.04.045

<a id="ref-9"></a>[9] Dhaliwal, B., Yuan, D., Pang, M. O. Y., et al. (2014). Crystal structure of IgE Fc in complex with CD23. *Journal of Immunology*, 192(11), 5391–5398. https://doi.org/10.4049/jimmunol.1303168

<a id="ref-10"></a>[10] Shade, K. T., Platzer, B., Washburn, N., et al. (2015). A single glycan on IgE is indispensable for initiation of anaphylaxis. *Journal of Experimental Medicine*, 212(4), 457–467. https://doi.org/10.1084/jem.20142182

<a id="ref-11"></a>[11] Gilfillan, A. M., & Tkaczyk, C. (2006). Integrated signalling pathways for mast-cell activation. *Nature Reviews Immunology*, 6(3), 218–230. https://doi.org/10.1038/nri1782

<a id="ref-12"></a>[12] Acharya, M., Borland, G., Edkins, A. L., et al. (2010). CD23/FcεRII: molecular multi-tasking. *Clinical & Experimental Immunology*, 162(1), 12–23. https://doi.org/10.1111/j.1365-2249.2010.04210.x

<a id="ref-13"></a>[13] Getahun, A., Hjelm, F., & Heyman, B. (2005). IgE enhances antibody and T cell responses in vivo. *Journal of